Pyrimethamine

Generic Name: Pyrimethamine

Brand Names: Daraprim

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₃ClN_₄

CAS Number: 58-14-0

Unique Ingredient Identifier: Z3614QOX8W

Background: One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

Indication: For the treatment of toxoplasmosis and acute malaria; For the prevention of malaria in areas non-resistant to pyrimethamine

Associated Conditions: Toxoplasmosis

Clinical Trials

Optimizing Reversal of HIV Latency With Combination Therapy

Phase 1

Not yet recruiting

Conditions: Hiv

Interventions: Drug: Panobinostat 20 MG Oral Capsule
Drug: Pyrimethamine 200mg Oral Tablet
Drug: Lenalidomide 25 MG Oral Capsule

First Posted Date: 2024-02-05

Last Posted Date: 2024-02-05

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 49

Registration Number: NCT06240520

Locations: 🇳🇱
Erasmus Medical Centre, Rotterdam, Zuid Holland, Netherlands
🇳🇱
Amsterdam University Medical Center, Amsterdam, Netherlands
🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands

CD40 Agonist and PD-1 Inhibitor in HNSCC

Phase 1

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: PD-1inhibitor - LVGN 3616
Drug: CD 40 Agonist - LVGN 7409

First Posted Date: 2023-12-07

Last Posted Date: 2025-02-17

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 20

Registration Number: NCT06159621

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma

Early Phase 1

Recruiting

Conditions: Head and Neck Cancer
Cancer of the Head and Neck

Interventions: Drug: Pyrimethamine

First Posted Date: 2023-01-10

Last Posted Date: 2025-04-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 22

Registration Number: NCT05678348

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Conditions

Phase 1

Conditions: Bioequivalence

Interventions: Drug: G-COSPE® tablets
Drug: Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine

First Posted Date: 2022-08-11

Last Posted Date: 2022-08-11

Lead Sponsor: Emzor Pharmaceutical Industries Limited

Target Recruit Count: 70

Registration Number: NCT05497063

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

Phase 1

Completed

Conditions: Therapeutic Equivalency

Interventions: Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug
Drug: Microgynon CD

First Posted Date: 2022-03-16

Last Posted Date: 2022-06-02

Lead Sponsor: Laboratorios Andromaco S.A.

Target Recruit Count: 36

Registration Number: NCT05282940

Locations: 🇮🇳
Azidus Laboratories Ltd., Chennai, Tamil Nadu, India

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Early Phase 1

Conditions: Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: CD19 CAR-T
Drug: CD22 CAR-T
Drug: CD 19+22
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-13

Lead Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Target Recruit Count: 50

Registration Number: NCT04626765

Locations: 🇨🇳
No.2 Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: BMS-986165
Drug: Pyrimethamine

First Posted Date: 2019-09-12

Last Posted Date: 2020-08-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT04086719

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ Challenge
Drug: Chloroquine Phosphate
Drug: Pyrimethamine
Drug: Coartem
Drug: ibuprofen

First Posted Date: 2019-05-16

Last Posted Date: 2022-07-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 252

Registration Number: NCT03952650

Locations: 🇲🇱
Malaria Vaccine Center STTB/MRTC, Bamako, Mali

LRAs United as a Novel Anti-HIV Strategy.

Phase 1

Completed

Conditions: HIV-1-infection

Interventions: Drug: Valproic Acid
Drug: Pyrimethamine

First Posted Date: 2018-05-16

Last Posted Date: 2021-04-29

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 28

Registration Number: NCT03525730

Locations: 🇳🇱
Erasmus MC, Rotterdam, Netherlands

Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Toxoplasmosis

Interventions: Drug: Pyrimethamine
Drug: Calcium folinate

First Posted Date: 2017-08-23

Last Posted Date: 2020-03-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 14

Registration Number: NCT03258762

Locations: 🇦🇺
GSK Investigational Site, Melbourne, Victoria, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy